Rationale for Antiplatelet Agents in Diabetic Vascular Disease
- 1 January 1978
- book chapter
- Published by Springer Nature
- Vol. 102, 243-256
- https://doi.org/10.1007/978-1-4757-1217-9_16
Abstract
Studies summarized in this paper indicate that some diabetics have increased sensitivity to platelet aggregating agents. The problem is in the platelet release reaction and may reflect increased synthesis of prostaglandins or their precursors. An interaction of plasma factors such as von Willebrand factor with platelets may also be involved. Based on these and other considerations, a prospective study on the use of aspirin and dipyridamole on diabetic lower extremity vascular disease is underway as a Veterans Administration Cooperative Study.Keywords
This publication has 33 references indexed in Scilit:
- Increased Synthesis of Prostaglandin-E-like Material by Platelets from Patients with Diabetes MellitusNew England Journal of Medicine, 1977
- Inhibition of labile aggregation-stimulating substance (LASS) and platelet aggregation in diabetes mellitusDiabetes, 1975
- INCREASED VON WILLEBRAND‐ANTIHAEMOPHILIC FACTOR A IN DIABETIC RETINOPATHYActa Ophthalmologica, 1974
- Etude de l'agrégation plaquettaire au cours de la rétino-pathie diabétique: Influence de l'hypophysectomieAtherosclerosis, 1974
- Platelet adhesiveness and aggregation in relation to diabetic retinopathyDiabetologia, 1971
- ADENOSINEDIPHOSPHATE INDUCED PLATELET ADHESIVENESS IN DIABETES MELLITUS WITH COMPLICATIONSActa Medica Scandinavica, 1971
- Platelet adhesiveness, plasma fibrinogen and factor VIII levels in diabetes mellitusDiabetologia, 1970
- Platelet aggregation and thrombus formation in diabetes mellitus: An in vitro studyPathology, 1970
- Platelet adhesiveness in diabetes mellitusJournal of Clinical Pathology, 1967
- DIABETIC RETINOPATHY AND RHEUMATOID ARTHRITISPublished by Elsevier ,1964